ORPHA:52503
X-linked creatine transporter deficiency
Also known as: Creatine transporter deficiency · SLC6A8 deficiency
Publications
1,844
Trials
3
Interventional, condition-specific
Researchers
1,182
Distinct authors in sample
Gene link
SLC6A8
Definitive
Readiness
6/6
Stages with a signal
Clinical definition (Orphanet)
X-linked creatine transporter deficiency (CRTR-D) is a creatine deficiency syndrome characterized clinically by global / (DD/ID) with prominent speech/language delay, autistic behavior and .
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0010305
- MeSH:C535598
- OMIM:300352
- UMLS:C1845862
- NCIT:C125665
Additional Mondo synonyms (4)
cerebral creatine deficiency syndrome 1 · cerebral creatine deficiency syndrome 1, X-linked recessive · cerebral creatine deficiency syndrome type 1 · creatine transporter deficiency
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
6/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — SLC6A8
- LiteraturePresent
1,844 matched papers (1,275 in last 10 years) Source
- Phenotype characterisedPresent
73 HPO annotations (e.g. Ptosis; Self-mutilation; Intellectual disability) Source
- Animal modelPresent
5 genotype models (Mus musculus) Source
- Orphan designationPresent
1 FDA designation (1 FDA orphan-indication approval) — e.g. cyclocreatine Source
- Interventional trialPresent
3 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (SLC6A8).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
73
Associated phenotypes · MONDO:0010305
- Ptosis
- Self-mutilation
- Intellectual disability
- Seizure
- Hypertonia
Showing 5 of 73 — open Monarch for the full list.
Animal models (Monarch / Alliance)
5
Model associations linked to this Mondo ID
- Slc6a8tm1.2Clar/Y [background:] involves: BALB/cJ * C57BL/6 * C57BL/6J * SJL·MGI:4941778·Mus musculus
- Slc6a8tm1.1Clar/Y Tg(Camk2a-cre)2Gsc/0 [background:] involves: C57BL/6 * C57BL/6J * FVB/N·MGI:5448415·Mus musculus
- Slc6a8tm1.2Lbar/Y [background:] involves: 129 * 129S1/Sv * C57BL/6J * C57BL/6N·MGI:5825026·Mus musculus
- Slc6a8tm1.2Lbar/Y [background:] involves: 129 * 129S1/Sv * C57BL/6N·MGI:5825021·Mus musculus
- Slc6a8tm1e(KOMP)Wtsi/Y [background:] involves: C57BL/6J * C57BL/6N·MGI:6197218·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
1
Designation · 1 with FDA orphan-indication approval
- FDA cyclocreatineCreatine transporter deficiency · 2012-06-18 · Not FDA Approved for Orphan Indication
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
1 associated chemical · 4 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Creatine · marker/mechanism
Pathways: Metabolism; Metabolism of polyamines; Creatine metabolism; Metabolism of amino acids and derivatives
Literature
Is anyone studying this?
1,844
1,844 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,844 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,275 in the last 10 years · low confidence
Phrase hits: 593 · MeSH hits: 0
Who's working on it?
1,182
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Salomons GS14 papers · 2025
Metabolic Unit, Department of Clinical Chemistry, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Papers in Europe PMC - 02Baroncelli L13 papers · 2026
Department of Developmental Neuroscience, IRCCS Stella Maris Foundation, I-56128 Pisa, Italy.
Papers in Europe PMC - 03Putignano E12 papers · 2026
Institute of Neuroscience, National Research Council (CNR), Via Moruzzi 1, 56124, Pisa, Italy.
Papers in Europe PMC - 04Porter FD11 papers · 2026
Section on Molecular Dysmorphology, Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA. Electronic address: fdporter@mail.nih.gov.
Papers in Europe PMC - 05Mabondzo A10 papers · 2025
Service de Pharmacologie et d'Immunoanalyse, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France.
Papers in Europe PMC - 06Skelton MR10 papers · 2026
Department of Pediatrics, University of Cincinnati College of Medicine & Division of Neurology, Cincinnati Children's Research Foundation, Cincinnati, OH, USA.
Papers in Europe PMC - 07Alessandrì MG9 papers · 2026
Department of Developmental Neuroscience, IRCCS Stella Maris Foundation, 56128, Pisa, Italy.
Papers in Europe PMC - 08Schulze A9 papers · 2026
Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, ON, M5G 1X8, Canada.
Papers in Europe PMC - 09Thurm A9 papers · 2026
National Institute of Mental Health, National Institutes of Health, Bethesda, MD.
Papers in Europe PMC - 10Longo N8 papers · 2026
Department of Pathology, University of Utah, ARUP Laboratories, Salt Lake City, UT, USA; Division of Medical Genetics, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
3
interventional trials for this specific condition
3 interventional trials matched this specific condition name; 2 currently recruiting in our sample.
Data as of 11 September 2026 · last trial check 28 July 2026
3 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 86.7th percentile).
low confidence · 86.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
3 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06018519·RECRUITING·Relevant Outcome Measures for Creatine Transporter Deficiency Patient
Not reviewed·Conditions: Creatine Transporter Defect·Matched via name phrase
- NCT06868979·RECRUITING·Optical Imaging in X-linked Disorders.
Not reviewed·Conditions: Fragile X Syndrome (FXS) · Creatine Transporter Deficiency·Matched via name phrase
Observational and natural-history studies
5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05600946·RECRUITING·Characterization of Dysmorphology in Subjects With Creatine Transporter Deficiency
Not reviewed·Conditions: Cognitive Disorder · Metabolic Disease · Autism Spectrum Disorder·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for X-linked creatine transporter deficiency — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("X-linked creatine transporter deficiency" OR "Creatine transporter deficiency" OR "SLC6A8 deficiency" OR "cerebral creatine deficiency syndrome 1" OR "cerebral creatine deficiency syndrome 1, X-linked recessive" OR "cerebral creatine deficiency syndrome type 1") OR (MESH:"Creatine deficiency, X-linked") OR ("SLC6A8" OR "SLC6A8 syndrome" OR "SLC6A8-related")MeSH descriptor terms unioned into the query: Creatine deficiency, X-linked
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"X-linked creatine transporter deficiency" OR "Creatine transporter deficiency" OR "SLC6A8 deficiency" OR "cerebral creatine deficiency syndrome 1" OR "cerebral creatine deficiency syndrome 1, X-linked recessive" OR "cerebral creatine deficiency syndrome type 1" OR "Creatine deficiency, X-linked"
Interventional trials matched via: phrase, mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 3 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1844) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T00:50:11.587Z
